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identified in exon 2 of FGB caused by c.221G> T† substitu-
tion, predicting the replacement of Arginine at position 74 
with a Leucine (p.Arg74Leu†) in a proband from a Kurdish 
family with dysfibrinogenaemia and familial venous and 
arterial thrombosis.
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Introduction
The generation of thrombin is the catalyst for the final step 
in the coagulation cascade for the conversion of soluble 
fibrinogen into insoluble fibrin polymer by the cleavage 
of the amino-termini of the α and β chains of fibrinogen, 
releasing fibrinopeptide A and B. The cleavage of fibrin-
opeptide A exposes new sites on the complex large fibrino-
gen molecule (composed of two identical subunits linked 
by a disulfide bond), these sites have high affinity for other 
fibrin molecules, leading to spontaneous fibrin polymeri-
zation with the formation of protofibrils. Fibrinopeptide B 
is released simultaneously with fibrinopeptide A but is not 
required for fibrin polymerization. The growing polymer is 
consolidated by the covalent bonding of the fibrin strands 
together through the action of the thrombin activated-trans-
glutaminase factor XIIIa leading to stabilization of the fri-
able platelet plug on which the fibrin polymer is deposited, 
later this is lysed by the fibrinolytic system [1].
Given that fibrinogen plays a pivotal role in both the 
pro-coagulant and fibrinolytic pathways, defects in fibrin-
ogen function may be associated with increased risk for 
both haemorrhage and thrombosis. Congenital dysfibrino-
genaemias, is a qualitative congenital fibrinogen disorder 
characterized by normal antigen levels of a dysfunctional 
Abstract Dysfibrinogenaemias may present in either con-
genital or acquired form and are disorders of fibrinogen 
structure which may or may not be associated with abnor-
mal function. More than 100 point mutations with single 
amino acid substitutions have been identified in over 400 
families. These lead to defective DNA in the translated 
fibrinogen molecule. Such cases have improved our under-
standing of the fibrinogen–fibrin structure. Six members 
of a consanguineous family including a female proband, a 
female sibling, three male siblings and a daughter, with ages 
between 29 years and 53 years presented with early onset 
venous and premature arterial thromboembolic disease 
were investigated for a pro-thrombotic tendency associ-
ated with dysfibrinogenaemia. The family was investigated 
using standard coagulation assays and DNA sequencing 
of the genes encoding the FGA, FGB and FGG. All cases 
have dysfibrinogenaemia with a fibrinogen level 1.4 to 1.5 
(1.9–4.3 g/L). Thrombophilia testing (including AT, PS & 
PC, F5 G1691A (FV Leiden)/F2 (prothombin G20210A) 
genotypes, homocysteine, antiphosphlipid antibody, parox-
ysmal nocturnal haemoglobinuria by flow cytometry and 
Janus Kinase-2 (exon 14)) were normal. PCR amplifica-
tion and sequencing of exon 2 of FBG revealed a heterozy-
gous mutation for a c.221G> T†substitution, predicting the 
replacement of the native Arginine at position 74 with a 
Leucine (p.Arg74Leu†). In silico analysis of p.Arg74Leu 
strongly support pathogenicity. A novel mutation was 
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fibrinogena [2]. It is a disorder of fibrinogen structure 
which may or may not be associated with abnormal func-
tion. Over 400 families with the congenital form [3] have 
been studied in whom structural defects were determined in 
approximately half of the cases [3–5]. The defects mostly 
result from DNA point mutations with single amino acid 
substitutions. Clinically, approximately half of affected 
individuals are asymptomatic [3, 4, 6] with a bleeding ten-
dency in a quarter and the remaining patients experience 
thrombosis with or without haemorrhage. In one study 55 % 
(n = 250) of patients were found incidentally [4]. Similarly, 
in a UK report 57 % (n = 35) were asymptomatic [7], and in 
the recent long-term study of 101 patients 58 % had an inci-
dental diagnosis, either during routine laboratory testing or 
before surgery [8]. The frequency of thrombosis was found 
to be higher in young women (mean age of first thrombosis 
was 27 years) with a high incidence of pregnancy-related 
thrombosis, especially in the postpartum period. Lower 
limb deep venous thrombosis predominates. In addition to 
an increased risk for thrombosis, there is a high frequency 
of pregnancy loss due to spontaneous abortions [9].
Although early studies involving over 2300 patients 
were insufficient to confirm a cause-effect relationship 
between dysfibrinogenaemia (reported in 1 % of patients) 
and VTE [6], later the International Society on Thrombosis 
and Haemostasis Scientific and Standardization Committee 
Subcommittee on Fibrinogen study convincingly supported 
causative association [6]. In a study of dysfibrinogenaemia 
with thrombophilia, 26 cases were evaluated along with 
187 relatives (99 had dysfibrinogenaemia and 88 did not), 
in which 20 of the relatives with dysfibrinogenaemia expe-
rienced a thrombotic event compared with none of those 
without dysfibrinogenemia. Additionally, several cases 
had >2 family members with both dysfibrinogenemia and 
thrombosis at a young age.
Investigations for congenital dysfibrinogenaemia include 
the thrombin time which is abnormally prolonged in all but 
few exceptions, this is considered the most sensitive screen-
ing test [3, 10]. In one study of 35 probands with dysfi-
brinogenemia from 15 families, the prothrombin time and 
the activated partial prothrombin time were found to have 
lower sensitivities of 96 and 65 %, respectively [11]. The 
prolonged thrombin time however have low specificity as 
it is prolonged for a variety of reasons [12] including; the 
presence of heparin [13] fibrin degradation products, excess 
fibrinogen, paraprotein [14] acquired antibodies to bovine 
thrombin, [15] excess protamine, autoantibodies against 
fibrinogen functional domains [16, 17] primary amyloi-
dosis [18] warfarin therapy [19] and hypoalbuminemia 
(<20 g/L) [20]. Reptilase time which uses an enzyme from 
snake venom (Bothrops atrox) instead of thrombin which 
cleaves fibrinopeptide A generating a clot. The reptilase 
time is used to detect heparin effect [21] where the reptilase 
time is consistently normal. Fibrinogen may be measured 
by functional (clot-based) method measuring only the func-
tional fibrinogen that participates in clot formation, this is 
the preferred assay when evaluating dysfibrinogen [22]. 
Other methods include immunologic (antigenic) or chemi-
cal (precipitation). A truly low fibrinogen level may be seen 
in consumptive states, dilutional coagulopathy, fibrinolytic 
therapy, severe hepatocellular disease, hereditary hypofi-
brinogenemia orafibrinogenemia, and dysfibrinogenemia.
Genetically, the three fibrinogen polypeptide chains (Aα, 
Bβ, and γ) are encoded by 3 separate genes on the long arm 
of chromosome 4 with autosomal dominance mode of trans-
mission of the various hereditary dysfibrinogens except in 
rare conditions [23]. In addition to its role in haemostasis, 
fibrinogen is also involved in wound healing, inflamma-
tion, cell migration and proliferation. Fibrinogen mutations 
have been implicated in the pathogenesis of other unrelated 
conditions including in hereditary amyloidosis [3]. Further 
information on fibrinogen mutation can be obtained from 
this link (http://www.geht.org/databaseang/fibrinogen) [24].
Case report
A 53 year-old female (Proband (case#1)) presented with 
first episode of deep vein thrombosis (DVT) two days fol-
lowing a 9-hour long haul flight at the age of 41  year, a 
first recurrence occurred 3  years later following the same 
trigger. These two episodes were managed with a limited 
period of anticoagulation. A further spontaneous recur-
rence of DVT and PE (first spontaneous event) was later 
diagnosed and is now established on long-term anticoagu-
lation with the vitamin-K antagonist warfarin. The family 
pedigree is shown in Fig. 1. The clinical characteristics of 
the other five affected members of the family are shown in 
Table  1. The table describes the thrombotic episode(s) in 
relation to site, type and the presence of triggering event 
and other risk factors. Case#6 sustained a VTE episode 
despite appropriate thromboprphylaxis with enoxaparin 
0.6  mg/kg daily S/C perioperatively for bariatric surgery. 
Figure 1 and Table 1 summarises the relevant clinical char-
acteristics and the family pedigree.
Methods and results
Coagulation screen and d‑dimer
In our Trust routinecoagulation screen consists of a Pro-
thrombin Time (PT), Activated Partial Thromboplastin 
Time (APTT) and a Clauss Fibrinogen (FIB) assay [25]. 
Thrombin Time (TT) and Reptilase time (RT) are also per-
formed upon request. Venous blood samples were collected 
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into 0·105  M tri-sodium citrate containing bottles and 
analysed using Sysmex coagulometers (Sysmex Corpora-
tion, Hamburg, Germany; CS2100i) with Dade-Behring 
(Marberg, Germany) reagents (PT—Innovin; APTT—
Actin FSL; TT—Thromboclotin reagent (1·25 μ/ml bovine 
thrombin); FIB—Thrombin reagent (10 IU/ml).
2nd degree
50 y.o. 62 y.o. 
.                                         
Consanguineous
53 y.o. 49 y.o. 45 y.o.             43 y.o.               41 y.o.                32 y.o.                  30 y.o. 
Ruptured AAA Rt-AVT & PE   Intrabdominal        Acute MI              
2 provoked DVTs post LHF                               Thrombosis
1 spontaneous DVT/PE Asymptomatic                        2 weeks post-BS                                Asymptomatic
31 y.o                29 y.o.            25 y.o.        18 y.o.   
Pregnancy-
associated DVT
AAA=Abdominal aortic aneurysm, AVT=Axillary vein thrombosis, BS=Bariatric Surgery, DVT=Deep vein thrombosis, MI=Myocardial infarction, 
LHF=long haul flight, PE=Pulmonary embolism, Rt=right, Y.O=years-old.
Fig. 1  Family pedigree
Table 1  Clinical characteristics of affected family members
AAA abdominal aortic aneurysm, DVT deep venous thrombosis, F female, M male, n/a not applicable, PE pulmonary embolism
Case#1 Case#2 Case#3 Case#4 Case#5 Case#6
Age (years) 53 49 43 41 31 29
Gender F M M M F F
Relation to proband Proband Sibling Sibling Sibling Sibling Daughter
History of venous 
thrombosis
Yes No Yes Yes No Yes
History of arterial 
thrombosis
No Yes No No Yes No
Site of thrombosis Leg DVT and PE Rupture of AAA Axillary vein 
thrombosis 
and PE
PE Acute Coronary 
syndrome
Leg DVT
Provoking trigger Yes in 2 episodes-
long haul flight
No No Yes No Yes
Spontaneous event Yes-one Yes Yes No Yes No
Timing of throm-
bosis
2 days post long-
haul flight
n/a n/a 14 days post-
surgery
n/a 8 weeks gestation








Fatal Fatal On anticoagulation
To assess duration
On dual antiplatelet 
therapy
Under surveillance
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The fully automated, computerised blood coagulation 
Sysmex analyser CS2100i uses closed vial sampling, uti-
lises a photo-optical detection method by passing multiple 
wavelengths of light delivered by fibre-optic cable through 
the patient-reagent mixture. The analyser detects changes 
in transmitted light intensity as the end-point conversion of 
fibrinogen to fibrin results in an increase in optical density. 
The coagulation curve is drawn using time as the X axis 
and transmitted light intensity as the Y axis. The clotting 
time end-point (in seconds) is determined where a 50 per-
cent change in optical density (OD) is reached for the PT, 
APTT, TT (660 nm) and FIB (405 nm).
The Innovance® immunoturbidimetric D-dimer assay 
employs polystyrene particles coated with D-dimer spe-
cific monoclonal antibodies. When mixed with the test 
plasma, an antigen–antibody reaction takes place, leading 
to agglutination of the latex microparticles in the presence 
of D-dimers resulting in an increase in turbidity which is 
detected as an increase in optical density (OD) measured at 
800 nm. The increase in OD is proportional to the level of 
D-dimer in the test sample where the delta change in OD 
is compared against a standard curve to quantitate D-dimer 
levels.
Thrombophilia tests
Venous blood samples were collected with minimal stasis 
using a 19-gauge butterfly needle into 0.105 M trisodium 
citrate. Platelet poor plasma was prepared by double cen-
trifugation of samples at 2700×g at room temperature for 
20 min. The plasma is then separated into freezer tubes ali-
quots (1.5 ml) and stored at −70 °C.
We determined antithrombin and protein C activities, 
free protein S antigen, F5 (FV Leiden) G1691/F2 (pro-
thrombin gene) G20210A genotypes and antiphospholipid 
screen comprising lupus anticoagulant, anticardiolipin and 
anti-β2GP-1 antibody in three subjects with objectively 
documented thrombosis. Table 2 summarises blood results 
for all general and prothrombotic work-up.
Chromogenic protein C and antithrombin assays
As described earlier, the analyser detects changes in 
transmitted light intensity at 405  nm. The optical density 
increases due to the increase in colour change caused by the 
cleaving of the respective chromogenic substrate (for pro-
tein C or AT) releasing pNA (p-nitroanilide). The increase 
in colour change is proportional to the level of Protein C or 
Antithrombin activity present in the respective sample.
Free protein S antigen assay
Monoclonal antibodies specific for free protein S are 
incorporated using Innovance® immunoturbidimetric 
method to quantitate levels of free Protein S as described 
above under D-dimer quantitation.
Activated protein C resistance (APCr)
APC resistance was assessed by measuring the anti-coag-
ulant response in plasma on the addition of APC (Dade 
ProC Global Kit). A ratio of <2.10 for the clotting time 
in the presence of APC/clotting time in the absence of 
APC was taken to represent APC resistance as described 
by Rosen et al [26]. Modified APCr (<2.20) is obtained 
as above but using Factor V deficient plasma, this is 
very sensitive to factor V mutations including Factor V 
Leiden.
Factor V Leiden and prothrombin G20210A
For factor V Leiden, exon 10 of the factor V gene was 
amplified by PCR using known primers, which contains the 
mutation G→A at nucleotide position 1691 as described 
by Bertina et al., 1994 [27]. The amplified DNA segment 
was then digested using the restriction enzyme MnlI (New 
England BioLabs) overnight at 37 °C, followed by electro-
phoresis separation in a 1.8 % agarose gel stained with eth-
idium bromide at a potential difference of 100 V and then 
examined under UV light. PCR amplification using specific 
primers generates a 267-bp fragment spanning the mutation 
site. The G1691A mutation on the factor V gene destroys 
a MnlI cleavage site. Digestion of the amplified fragment 
with MnlI generates three fragments—37, 67 and 163  bp 
in length—in the presence of normal factor V genotype. 
In the presence of the affected allele, digestion with MnlI 
generates two fragments—67 and 200 bp in length. A hete-
rozygous sample would therefore generate four bands—37, 
67, 163 and 200 bp in length—and a homozygous sample 
would generate only two bands—67 and 200 bp in length.
For prothrombin G20210A, PCR using specific primers 
was used to amplify a 345-bp segment, followed by over-
night digestion with the restriction endonuclease HindIII at 
37 °C, followed by gel electrophoresis (Poort et  al., 1996) 
[28]. The G20210A mutation in the 3′ untranslated region 
of the prothrombin gene does not disrupt a natural recogni-
tion site for any restriction endonuclease. The primers used 
are designed to introduce a HindIII cleavage site only if the 
mutant allele is present. Following digestion with HindIII 
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one fragment of 345 bp is yielded in a normal individual, 
two fragments of 322 and 23  bp in a homozygous indi-
vidual and three fragments of 345, 322 and 23 bp in a het-
erozygous individual.
Antiphospholipid antibodies
Lupus anticoagulant is detected using the dilute Russell’s 
viper venom time (dRVVT) together with a neutralization 
step with phospholipid. Patient samples with a dRVVT 
ratio (test/control) of ≥ 1.2 were retested with a neutraliza-
tion step with phospholipid. A decrease of 10 % or more in 
the ratio was considered to be positive for lupus anticoagu-
lant [29]. Anticardiolipin and anti-β2GP-1 antibodies and 
were identified using a standardized enzyme linked immu-
nosorbent assay (ELISA) [30, 31]. Initial positive test for 
LA, positive aCL titre, or positive anti-β2GP-1 antibody 
had a confirmatory test performed on a second sample 
taken at least 12 weeks later. Only patients with persistently 
positive tests were considered to have the antiphospholipid 
syndrome.
Analysis of the fibrinogen genes
Causative single nucleotide variations (SNVs) were sought 
by polymerase chain reaction amplification and sequencing 
of FGA exon 2, FGG exon 2 and FGG exon 8, which are 
hotspots in the GEHT dysfibrinogenaemia mutation data-
base [24]. The remaining coding sequences of FGA, FGB 
and FGG were sequenced in subjects with previously unre-
ported candidate SNVs. In our family, PCR amplification 
and sequencing of exon 2 of FBG showed the proband to 
be heterozygous for a c.221G> T† substitution, predict-
ing the replacement of the native Arginine at position 74 
with a Leucine (p.Arg74Leu†) (LSDB:http://www.geht.
Table 2  Summary of blood results
Anti-β2GP-I anti-β 2Glycoprotein-I, FLAER fluorescent aerolysin, dRVVT dilute Russell Viper Venom Test, n/a not available
Test Normal range Index Case#1 Case#4 Case#6
White blood cell count 4.2–11.2 × 109/L 5.9 7.7 8.3
Haemoglobin 114–150 g/L 126 148 125
Platelet count 135–400 × 109/L 226 233 234
Prothrombin time (PT) 9.4–11.3 s 11.9 12.1 13.0
Activated partial thromboplastin time 
(APTT)
25.0–30.7 s 28.1 32.1 25.4
Thrombin time (TT) 12.9–15.2 s 26.2 25.7 23.4
Reptilase time (RT) 15–19 s 27.1 28.3 26.7
Fibrinogen 1.9–4.3 g/L 1.51 1.62 1.55
D-dimer <560 ug/L 238 ug/L 217 169
Anti-thrombin activity 0.80–1.4 iu/L 0.84 1.2 0.97
Protein-C activity 0.65–1.35 iu/L 1.32 1.17 1.28
Protein-S-free antigen 0.66–1.54 iu/L 0.79 0.94 0.88
Factor V Leiden genotype G/G G/G G/G G/G
G20210A G/G G/G G/G G/G
Factor VIII activity 0.6–1.43 iu/L 0.71 1.30 1.17
Fibrin plate lysis 0.65–1.20 1.29 n/a n/a
















Activated protein C resistance 2.10–4.60 3.36 4.0 2.73
Modified activated protein C resistance 2.20–2.70 2.91 2.5 2.1
PNH immunophenotyping Granulocyte CD24 and FLAER
Monocyte CD14 and FLAER
Red cells CD 59
No clone detected No clone detected No clone detected
JAK-2 exon-14 5 % detection level by PCR Not detected Not detected Not detected
Fibrinogen gene mutation analysis Exon 2 of FGB caused 
by c.221G> T substi-
tution
Not done Not done
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org/fr/pages/set_pratique03a.html). This is a novel muta-
tion. Analysis of the coding regions of FGA, FGB, FGG 
has been completed and no additional putative mutations 
identified.
In silico analysis
In silico is an expression used to indicate the of computer 
software simulation to predict impact of an abnormaility 
inclusing genetic mutations. The expression in silico was 
first used in 1989. This is now widely used by diagnostics 
laboratories as a splice prediction tools to predict the effect 
of a genetic variant. In our study, in silico analysis using 
ALAMUT software (http://www.interactive-biosoftware.
com/doc/alamut-visual/2.8) predicted that p.Arg74Leu 
mutation strongly support pathogenicity [32].
Discussion
The exact mechanism by which dysfibrinogenemia 
increases thrombosis risk is not well understood, biologi-
cally, this may occur due to either excessive thrombosis 
through increased thrombin generation and clot formation 
or impaired fibrinolysis and clot lysis. Mechanistically this 
depends on the specific fibrinogen defect. Defective bind-
ing of thrombin by the abnormal fibrinogen molecule was 
postulated resulting in excess circulating thrombin which 
activates platelet [33–35]. Alternatively, impaired fibrinoly-
sis as a result of defective binding of tissue-type plasmi-
nogen activator [35] or lysis-resistance to plasmin [36, 37] 
has been suggested. The prothrombotic correlation of dys-
fibrinogens is found in the following fibrinogens including; 
Caracas V, Chapel Hill III, Christchurch II & III, V Mar-
burg, Germany-k, Hannover II, Ijmuiden, Melun, Milano 
III, New York I, Nigmegen, London VII, Paris V, Lissin-
gen/Frankfurt IV [3]. These 15 “thrombophilic” dysfibrin-
ogens have mutations that are predominantly found in the 
C-terminal domain of the Aα chain and the thrombin cleav-
age site of the Bβ chain [6].
Molecular defects due to heterozygous missense muta-
tions localized in exon 2 of FGA and exon 8 of FGG, lead 
to defects in fibrinogen to fibrin conversion, fibrin network 
formation, and other fibrinogen functions. As most individ-
uals with the condition are heterozygous, they have circu-
lating mixture of normal and abnormal fibrinogen. More-
over, the molecular basis for the defect and the resulting 
symptoms (genotype-phenotype correlation) vary greatly. 
The analysis of dysfibrinogens at the molecular level has 
been challenging due to the size and complexity of the 
fibrinogen molecule but overall the defects can be separated 
into two major groups. Those which affects the release of 
the fibrinopeptides A and B, and those that do not. The 
first group tends to associate with bleeding complications 
because they interfere with the initial conversion of solu-
ble fibrinogen to fibrin monomer [2] and they account for 
the majority of abnormal fibrinogens and include substitu-
tions of amino acids situated at the amino-terminal regions 
of the α and β chains, specifically at or near the thrombin-
cleavage sites [38]. The other more heterogeneous group, 
vary clinically from asymptomatic, to severe bleeding, to 
severe thrombophilia and comprises mutations within the 
globular carboxyl-terminal regions of the three chains as 
well as mutations at the polymerization sites. The geno-
type-phenotype correlation in this group have not been well 
characterized.
It is now accepted that the symptoms associated with 
various dysfibrinogenemias may be modulated by coexist-
ing factors. As predisposition to thrombosis is often multi-
factorial and may be the result of more than one mutation in 
genes encoding haemostasis proteins [39], thrombophiliac 
dysfibrinogenemia may interact synergistically with other 
genetic and non-genetic risk factors such as trauma, preg-
nancy, oral contraceptives, hormone replacement, surgery 
and cancer. Several examples illustrate this phenomenon 
including the heterozygous dysfibrinogemias Cedar Rapids 
(R275C) [40] and Giessen IV (D318G) [5] both of which 
were reported in association with a heterozygous factor V 
Leiden mutation. In the Cedar Rapids family, either defect 
alone was not associated with symptoms, but the double 
mutation was strongly associated with pregnancy-related 
thrombosis. The complex interactions with potential risk 
factors would explain partially the variability observed 
in the clinical symptoms. In the case of the D364, N308 
and R275 mutations, the clinical manifestations associ-
ated with a given molecular defect varied greatly from one 
patient to another from being silent or with mild haemor-
rhage to severe thrombophilia [41]. As few genotypes are 
clearly correlated with a clinical phenotype [5], this makes 
the clinical management a great challenge. Even asympto-
matic persons are at risk of developing cardiovascular and/
or major bleeding events during the natural course of the 
disease [8].
To our knowledge this novel is a unique mutation in this 
ethnic population. The Kurdish population is known for its 
common practice of consanguinity, therefore, this is likely 
to be a prevalent finding. In our family, thrombosis affected 
both genders in keeping with autosomal dominance pattern 
with both venous and arterial thrombosis presenting prema-
turely with age ranging from 29 to 49 years. In common 
with other similar conditions, there is a demonstrable trig-
ger for at least four of venous thrombotic episodes varying 
from Long-haul travel to pregnancy-associated. One male 
sibling sustained a post-operative PE following bariat-
ric surgery despite carful perioperative thromprophylactic 
strategy. Two male deaths occurred at 43 and 49 years due 
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to fatal pulmonary embolism and ruptured atheomatous 
abdominal aortic aneurysm respectively. In our patients, 
the preliminary coagulation screens including significantly 
prolonged thrombin time and low functional fibrinogen 
concentration were highly suggestive of dysfibrinogenae-
mia. As in this family, thrombophilic defect are equally 
important to consider in view of young age and the dispro-
portionate degree of the thrombotic episodes in relation to 
the provoking events. This is a novel thrombophilic fibrino-
gen which is found in a defined ethnic group of Kurdish 
descent and the finding of low fibrinogen in individuals of 
such ethnic group would benefit them from the appropri-
ate thrombosis risk analysis and advice for risk reduction 
measures for both venous and arterial thrombosis including 
the avoidance of estrogen contraceptives and implementing 
aggressive thromboprophylaxis. Our paper is significantly 
limited by the lack of genotype information on other mem-
bers of the family, affected or unaffected, the lack of moti-
vation in other members of the family in providing blood 
samples coupled by concerns about labeling them with a 
potential genetic condition presented an obstacle for this 
despite clinical counseling. Furthermore, the cost of the 
analysis is not covered under routine national health ser-
vice (NHS) pathology funding. The fibrinogen gene analy-
sis is performed in a regional genetic laboratory hosted by 
another institute, in contrast to the thrombophilia testing 
which is performed in house. Further investigations with 
other patients from similar ethnic background will hope-
fully shed more light on the significance of this genetic 
mutation.
Conclusions
It is critical to evaluate the contribution of other risk fac-
tors in patients with dysfibrinogenemia. This is to ascertain 
if the dysfibrinogenemia is the sole thrombotic risk fac-
tor present in each individual. The elucidation of crystal 
structures of fibrinogen fragments has shed further light on 
the arrangement of domains and the interactions between 
amino acid residues that are vital for the various functions 
of this complex molecule. The effects of mutations that 
cause dysfibrinogenemias can now be explored through 
further structure–function studies, functional analysis of 
polymerization and fibrinolysis, viscoelastic properties of 
fibrin clot. Future research will lead to a better understand-
ing, diagnosis and management of the condition.
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